DGAP-News

Press Release 4SC AG: Dr Susanne Danhauser-Riedl joins 4SC as Chief Medical Officer to strengthen management and clinical development team

DGAP-News: 4SC AG / Key word(s): Change of Personnel/Miscellaneous
Press Release 4SC AG: Dr Susanne Danhauser-Riedl joins 4SC as Chief
Medical Officer to strengthen management and clinical development team

01.04.2015 / 07:30

---------------------------------------------------------------------

Press Release

Dr Susanne Danhauser-Riedl joins 4SC as Chief Medical Officer to strengthen
management and clinical development team

Planegg-Martinsried, Germany, 1 April 2015 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for cancer and autoimmune diseases, today announced the
appointment of Dr Susanne Danhauser-Riedl as the Company's Chief Medical
Officer (CMO). Dr Danhauser-Riedl will take over management of clinical
development at 4SC AG from 1 April 2015 and thus assume responsibility for
the further clinical development of the Company's oncology pipeline,
including the compounds resminostat, 4SC-202 and 4SC-205. As Chief Medical
Officer, she will report directly to Management Board Member and Chief
Development Officer (CDO) & Chief Scientific Officer (CSO) Dr Daniel Vitt.

Dr Susanne Danhauser-Riedl is a medical doctor and has long standing
experience in the fields of haematology and oncology. She has over 20 years
of management experience both in research and clinical practice and in the
fields of Medical Affairs and clinical development in the pharmaceutical
industry. Prior to joining 4SC, she spent almost ten years at the
pharmaceutical company GlaxoSmithKline GmbH & Co. KG (GSK). At GSK she held
responsibility for the complete Life Cycle Management including clinical
development of the oncology portfolio in Germany serving as Medical Head
Haematology/Oncology and, from 2012, as Medical Head Haematology/Head
Regional Medical Advisors. Before joining GSK, Dr Danhauser-Riedl spent
four years in the field of Medical Affairs at MedacSchering Onkologie GmbH,
most recently as Head of Medical Affairs and Drug Safety. Before that she
worked over twelve years as a medical doctor and research scientist in
haematology/oncology at a number of university hospitals in Munich,
Germany. Her positions there included Head of Immunophenotyping at the
Specialist Leukaemia Diagnostics Lab (University Hospital, LMU Munich,
Großhadern campus) and Head of the Immunocytology Lab within the Department
of Haematology (University Hospital, LMU Munich, City campus).

Dr Danhauser-Riedl studied medicine at the University of Regensburg and at